lncRNA546 urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone https://t.co/mFkZIm3elQ https://t.co/EsrTi2LkTO
New article: Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone https://t.co/UFjE7uHitp #prostatecancer #oncology https://t.co/9OEq3uED2L
Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone: Background and objectives Prostate specific antigen (PSA) is currently #oncology… https://t.co/Ji
New research: Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone: Background and objectives Prostate specific antigen (PSA) is currently… https://t.c